Method of producing biospecific molecules by protein trans-splicing
First Claim
1. A method of producing a bispecific molecule having a first antigen recognition portion that binds a C3b-like receptor and a second antigen recognition portion that binds a pathogenic antigenic molecule, comprising contacting an N-intein first antigen recognition portion and a C-intein second antigen recognition portion under conditions such that protein trans-splicing occurs, wherein said N-intein first antigen recognition portion comprises said first antigen recognition portion conjugated to the amino terminus of an N-intein of a split intein, and wherein said C-intein second antigen recognition portion comprises said second antigen recognition portion conjugated to the carboxy terminus of a C-intein of said split intein, wherein the amino acid residue immediately at the C-terminal side of the splice junction of said C-intein is an amino acid residue selected from the group consisting of cysteine, serine, and threonine.
1 Assignment
0 Petitions
Accused Products
Abstract
The invention provides methods of using protein trans-splicing for the production of bispecific molecule which has a first antigen recognition portion that binds a C3b-like receptor and a second antigen recognition portion that binds an antigenic molecule present in the circulatory system of a mammal. The invention also provides bispecific molecules produced by protein trans-splicing. The bispecific molecules of the invention can be used for the clearance of pathogenic antigenic molecules from the circulatory system of a mammal. The invention further provides methods of using protein trans-splicing for the production of polyclonal libraries of bispecific molecules, which comprise populations of bispecific molecules with different antigen recognition specificities. Such polyclonal libraries of bispecific molecules can be used for targeting multiple epitopes of a pathogenic antigenic molecule and/or multiple variants of a pathogenic antigenic molecule.
47 Citations
183 Claims
- 1. A method of producing a bispecific molecule having a first antigen recognition portion that binds a C3b-like receptor and a second antigen recognition portion that binds a pathogenic antigenic molecule, comprising contacting an N-intein first antigen recognition portion and a C-intein second antigen recognition portion under conditions such that protein trans-splicing occurs, wherein said N-intein first antigen recognition portion comprises said first antigen recognition portion conjugated to the amino terminus of an N-intein of a split intein, and wherein said C-intein second antigen recognition portion comprises said second antigen recognition portion conjugated to the carboxy terminus of a C-intein of said split intein, wherein the amino acid residue immediately at the C-terminal side of the splice junction of said C-intein is an amino acid residue selected from the group consisting of cysteine, serine, and threonine.
-
2. A method of producing a bispecific molecule having a first antigen recognition portion that binds a C3b-like receptor and a second antigen recognition portion that binds a pathogenic antigenic molecule, comprising:
-
(a) obtaining an N-intein first antigen recognition portion by conjugating said first antigen recognition portion to the amino terminus of a molecule comprising an N-intein of a split intein;
(b) obtaining a C-intein second antigen recognition portion by conjugating said second antigen recognition portion to the carboxy terminus of a molecule comprising a C-intein of said split intein, wherein the amino acid residue immediately at the C-terminal side of the splice junction of said C-intein is an amino acid residue selected from the group consisting of cysteine, serine, and threonine; and
(c) contacting said N-intein first antigen recognition portion and said C-intein second antigen recognition portion under conditions such that protein trans-splicing occurs, to produce said bispecific molecule.
-
-
32. A method of producing a bispecific molecule having a first antigen recognition portion that binds a C3b-like receptor and a second antigen recognition portion that binds a pathogenic antigenic molecule, comprising
(a) contacting an N-intein first antigen recognition portion and a C-intein streptavidin under conditions such that trans-splicing occurs to produce a first antigen recognition portion-streptavidin molecule, wherein said N-intein first antigen recognition portion comprises said first antigen recognition portion conjugated to the amino terminus of an N-intein of a split intein, and wherein said C-intein streptavidin comprises a core streptavidin conjugated to the carboxy terminus of a C-intein of said split intein, wherein the amino acid residue immediately at the C-terminal side of the splice junction of said C-intein is an amino acid residue selected from the group consisting of cysteine, serine, and threonine; - and
(b) contacting said first antigen recognition portion-streptavidin molecule and a biotinylated second antigen recognition portion under conditions conducive to binding between streptavidin and biotin, to produce said bispecific molecule. - View Dependent Claims (34, 35, 36, 37, 38, 39, 40, 41)
- and
-
33. A method of producing a bispecific molecule having a first antigen recognition portion that binds a C3b-like receptor and a second antigen recognition portion that binds a pathogenic antigenic molecule, comprising:
-
(a) obtaining an N-intein first antigen recognition portion by conjugating said first antigen recognition portion to the amino terminus of an N-intein of a split intein;
(b) obtaining a C-intein streptavidin by conjugating a core streptavidin to the carboxy terminus of the C-intein of said split intein, wherein the amino acid residue immediately at the C-terminal side of the splice junction of said C-intein is an amino acid residue selected from the group consisting of cysteine, serine, and threonine;
(c) contacting said N-intein first antigen recognition portion and said C-intein streptavidin under conditions such that protein trans-splicing occurs, to produce a first antigen recognition portion-streptavidin molecule, wherein said first antigen recognition portion is conjugated to said streptavidin;
(d) obtaining a biotinylated second antigen recognition portion; and
(e) contacting said first antigen recognition portion-streptavidin molecule and said biotinylated second antigen recognition portion under conditions conducive to binding between streptavidin and biotin, to produce said bispecific molecule.
-
- 42. A method of producing a polyclonal library of bispecific molecules, each member of said polyclonal library having a first antigen recognition portion that binds a C3b-like receptor and a second antigen recognition portion that binds a pathogenic antigenic molecule, comprising contacting a plurality of N-intein first antigen recognition portions and a plurality of different C-intein second antigen recognition portions under conditions such that protein trans-splicing occurs to produce a polyclonal library of bispecific molecules, wherein each of said plurality of N-intein first antigen recognition portions comprises said first antigen recognition portion conjugated to the amino terminus of an N-intein of a split intein, and wherein each of said plurality of C-intein second antigen recognition portions comprises a second antigen recognition portion having a different binding specificity conjugated to the carboxy terminus of a C-intein of said split intein, wherein the amino acid residue immediately at the C-terminal side of the splice junction of said C-intein is an amino acid residue selected from the group consisting of cysteine, serine, and threonine.
-
43. A method of producing a polyclonal library of bispecific molecules, each member of said polyclonal library having a first antigen recognition portion that binds a C3b-like receptor and a second antigen recognition portion that binds a pathogenic antigenic molecule, comprising:
-
(a) obtaining a plurality of N-intein first antigen recognition portions by a method comprising conjugating each of a plurality of first antigen recognition portions to the amino terminus of an N-intein of a split intein;
(b) selecting from a phage display library a plurality of phage that display antigen recognition polypeptides, each having a different respective binding specificity using affinity screening;
(c) obtaining a plurality of nucleic acids encoding said plurality of antigen recognition polypeptides, respectively;
(d) fusing each nucleic acid of said plurality of nucleic acids to the amino terminus of a C-intein of said split intein to obtain a plurality of nucleic acids encoding a plurality of C-intein antigen recognition portions, wherein the amino acid residue immediately at the C-terminal side of the splice junction of said C-intein is an amino acid residue selected from the group consisting of cysteine, serine, and threonine;
(e) expressing said plurality of nucleic acids encoding said plurality of C-intein antigen recognition portion fragments in a host;
(f) obtaining said plurality of C-intein antigen recognition portions from said host; and
(g) contacting said plurality of C-intein antigen recognition portions and a plurality of said N-intein first antigen recognition portions under conditions such that protein trans-splicing occurs, to produce said polyclonal library of bispecific molecules. - View Dependent Claims (49, 50)
-
-
44. A method of producing a polyclonal library of bispecific molecules, each member of said polyclonal library having a first antigen recognition portion that binds a C3b-like receptor and a second antigen recognition portion that binds a pathogenic antigenic molecule, comprising:
-
(a) obtaining a plurality of N-intein first antigen recognition portions by a method comprising conjugating each of a plurality of first antigen recognition portions to the amino terminus of an N-intein of a split intein;
(b) fusing the amino terminus of the nucleic acid encoding a polypeptide antibody in each member of said phage display library to the carboxy terminus of a C-intein of said split intein to obtain a phage display library displaying a repertoire of C-intein antigen recognition portions, wherein the amino acid residue immediately at the C-terminal side of the splice junction of said C-intein is an amino acid residue selected from the group consisting of cysteine, serine, and threonine;
(c) selecting from said phage display library displaying a repertoire of C-intein antigen recognition portions a plurality of phage that display C-intein antigen recognition portions, each having a different respective binding specificity using affinity screening;
(d) obtaining a plurality of nucleic acids encoding said plurality of C-intein antigen recognition portions, respectively;
(e) expressing said plurality of nucleic acids encoding said plurality of C-intein antigen recognition portions in a host;
(g) obtaining said plurality of C-intein antigen recognition portions from said host; and
(h) contacting said plurality of C-intein antigen recognition portions and a plurality of said N-intein first antigen recognition portions under conditions such that protein trans-splicing occurs, to produce said polyclonal library of bispecific molecules.
-
-
45. A method of producing a polyclonal library of bispecific molecules, each member of said polyclonal library having a first antigen recognition portion that binds a C3b-like receptor and a second antigen recognition portion that binds a pathogenic antigenic molecule, comprising
(a) contacting a population of N-intein first antigen recognition portions and a population of C-intein streptavidin under conditions such that protein trans-splicing occurs to produce a population of first antigen recognition portion-streptavidin molecules, wherein each of said plurality of N-intein first antigen recognition portions comprises said first antigen recognition portion conjugated to the amino terminus of an N-intein of a split intein, and wherein each of said plurality of C-intein streptavidin comprises a core streptavidin conjugated to the carboxy terminus of a C-intein of said split intein, wherein the amino acid residue immediately at the C-terminal side of the splice junction of said C-intein is an amino acid residue selected from the group consisting of cysteine, serine, and threonine; - and
(b) contacting said population of first antigen recognition portion streptavidin molecule and a plurality of biotinylated second antigen recognition portions, each having a different antigen recognition specificity under conditions conducive to binding between streptavidin and biotin, to produce said polyclonal library of bispecific molecules.
- and
-
46. A method of producing a polyclonal library of bispecific molecules, each member of said polyclonal library having a first antigen recognition portion that binds a C3b-like receptor and a second antigen recognition portion that binds a pathogenic antigenic molecule, comprising:
-
(a) obtaining a population of N-intein first antigen recognition portions by a method comprising conjugating each of a population of first antigen recognition portions to the amino terminus of an N-intein of a split intein;
(b) obtaining a population of C-intein streptavidin by a method comprising conjugating each of a population of core streptavidins to a C-intein of said split intein, wherein the amino acid residue immediately at the C-terminal side of the splice junction of said C-intein is an amino acid residue selected from the group consisting of cysteine, serine, and threonine;
(c) contacting said population of N-intein first antigen recognition portions with said population of C-intein streptavidins under conditions such that protein trans-splicing occurs to produce a population of first antigen recognition portion streptavidin molecules;
(d) selecting from a phage display library a plurality of phage that display antigen recognition polypeptides, each having a different respective binding specificity using affinity screening;
(f) obtaining a plurality of nucleic acids encoding said plurality of antigen recognition polypeptides, respectively;
(g) expressing said plurality of nucleic acids encoding said plurality of antigen recognition polypeptides in a host;
(h) obtaining said plurality of antigen recognition polypeptides from said host;
(i) obtaining a plurality of biotinylated antigen recognition polypeptides by conjugating each member of said plurality of antigen recognition polypeptides with biotin using an activated biotin agent; and
(j) contacting said plurality of biotinylated antigen recognition polypeptides and said population of first antigen recognition portion streptavidin molecules under conditions conducive to binding between streptavidin and biotin, to produce said polyclonal library of bispecific molecules.
-
-
51. A method of producing a C-intein antigen recognition portion phage display library, each phage in said C-intein antigen recognition portion phage display library displaying on its surface a different C-intein antigen recognition portion, comprising fusing the amino terminus of the nucleic acid encoding a polypeptide antibody in each of a plurality of members of a phage display library to the carboxy terminus of a C-intein of a split intein to obtain a phage display library displaying a repertoire of C-intein antigen recognition portions, wherein the amino acid residue immediately at the C-terminal side of the splice junction of said C-intein is an amino acid residue selected from the group consisting of cysteine, serine, and threonine.
-
52. A bispecific molecule, comprising:
-
(a) a first antigen recognition portion that binds a C3b-like receptor; and
(b) a second antigen recognition portion that binds a pathogenic antigenic molecule;
wherein said first antigen recognition portion comprises a monoclonal antibody, and wherein said second antigen recognition portion is conjugated to a carboxy terminus of a heavy or light chain of said first antigen recognition portion. - View Dependent Claims (59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72)
-
-
53. A bispecific molecule, comprising:
-
(a) a first antigen recognition portion that binds a C3b-like receptor;
(b) a linker; and
(c) a second antigen recognition portion that binds a pathogenic antigenic molecule;
wherein said second antigen recognition portion is conjugated to a carboxy terminus of said first antigen recognition portion via said linker. - View Dependent Claims (54, 55, 56, 57, 58)
-
- 73. A polyclonal library of bispecific molecules comprising a plurality of bispecific molecules each comprising (a) a first antigen recognition portion that binds a C3b-like receptor, and (b) a different second antigen recognition portion, said different second antigen recognition portions having different binding specificities, wherein said first antigen recognition portion comprises a monoclonal antibody, and wherein said second antigen recognition portion is conjugated to a carboxy terminus of said first antigen recognition portion.
-
74. A polyclonal library of bispecific molecules comprising a plurality of bispecific molecules, each comprising:
-
(a) a first antigen recognition portion that binds a C3b-like receptor;
(b) a linker; and
(c) a different second antigen recognition portion having a different binding specificity;
wherein said second antigen recognition portion is conjugated to a carboxy terminus of said first antigen recognition portion via said linker. - View Dependent Claims (75, 76, 77, 78, 79)
-
-
93. A composition comprising a plurality of purified bispecific molecules, wherein each bispecific molecule of said plurality of purified bispecific molecules comprises a first antigen recognition portion that binds a C3b-like receptor and a second antigen recognition portion that binds a pathogenic antigenic molecule, wherein said first antigen recognition portion comprises a monoclonal antibody, and wherein said second antigen recognition portion is conjugated to a carboxy terminus of a heavy or light chain of said first antigen recognition portion, said plurality of purified bispecific molecules each comprising a different second antigen recognition portions that has a different binding specificity.
-
94. A composition comprising a plurality of purified bispecific molecules, wherein each bispecific molecule of said plurality of purified bispecific molecules comprises:
-
(a) a first antigen recognition portion that binds a C3b-like receptor; and
(b) a second antigen recognition portion that binds a pathogenic antigenic molecule;
wherein said first antigen recognition portion comprises a monoclonal antibody, and wherein said second antigen recognition portion is conjugated to a carboxy terminus of a heavy or light chain of said first antigen recognition portion, said plurality of purified bispecific molecules each comprising a different second antigen recognition portions that has a different binding specificity.
-
-
95. A molecule, comprising:
-
(a) an antigen recognition portion that binds a C3b-like receptor; and
(b) an N-intein moiety comprising an N-intein of a split intein;
wherein said antigen recognition portion is conjugated to the amino terminal end of said N-intein moiety. - View Dependent Claims (96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109)
-
-
110. A molecule, comprising:
-
(a) an antigen recognition portion; and
(b) a C-intein moiety comprising a C-intein of a split intein;
wherein said antigen recognition portion is conjugated to the carboxy terminal end of said C-intein moiety, and wherein the amino acid residue immediately at the C-terminal side of the splice junction of said C-intein is an amino acid residue selected from the group consisting of cysteine, serine, and threonine. - View Dependent Claims (111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121)
-
-
122. A molecule, comprising:
-
(a) a streptavidin; and
(b) a C-intein of a split intein comprising, immediately at the C-terminal side of the splice junction, an amino acid residue selected from the group consisting of cysteine, serine, and threonine;
wherein said streptavidin is conjugated to the carboxy terminus of said C-intein. - View Dependent Claims (123, 124, 125, 126, 127, 128)
-
-
129. A C-intein antigen recognition portion phage display library, comprising a plurality of phage, each phage in said plurality displaying on its surface a different C-intein polypeptide fusion protein, wherein each polypeptide has a different binding specificity.
-
130. An expression vector, comprising a transcriptional regulatory element operably linked to a nucleotide sequence encoding a first antigen recognition portion that binds a C3b-like receptor fused to the amino terminus of the N-intein of a split intein.
-
131. An expression vector, comprising a transcriptional regulatory element operably linked to a nucleotide sequence encoding a second antigen recognition portion fused to the carboxy terminus of a C-intein of a split intein wherein the amino acid residue immediately at the C-terminal side of the splice junction of said C-intein is an amino acid residue selected from the group consisting of cysteine, serine, and threonine.
-
132. An expression vector, comprising a transcriptional regulatory element operably linked to a nucleotide sequence encoding a core streptavidin fused to the carboxy terminus of a C-intein of a split intein wherein the amino acid residue immediately at the C-terminal side of the splice junction of said C-intein is an amino acid residue selected from the group consisting of cysteine, serine, and threonine.
- 133. A nucleic acid encoding an N-intein fused to the carboxy terminus of a heavy chain of an anti-CR1 monoclonal antibody.
-
134. An expression vector, comprising a transcriptional regulatory element operably linked to a nucleotide sequence encoding an N-intein fused to the carboxy terminus of a heavy chain of an anti-CR1 monoclonal antibody.
-
135. A nucleic acid encoding an N-intein fused to the carboxy terminus of the light chain of an anti-CR1 monoclonal antibody.
-
136. An expression vector, comprising a transcriptional regulatory element operably linked to a nucleotide sequence encoding an N-intein fused to the carboxy terminus of a light chain of an anti-CR1 monoclonal antibody.
-
140. A nucleic acid encoding an N-intein fused to the carboxy terminus of the Fc domain that is fused to a scFv.
-
141. An expression vector, comprising a transcriptional regulatory element operably linked to a nucleotide sequence encoding an N-intein fused to the carboxy terminus of the Fc domain that is fused to a scFv.
-
142. A nucleic acid encoding a C-intein fused to the amino terminus of a polypeptide that binds an antigen.
-
143. An expression vector, comprising a transcriptional regulatory element operably linked to a nucleotide sequence encoding a C-intein fused to the amino terminus of polypeptide that binds an antigen.
-
144. A nucleic acid encoding a C-intein fused to the amino terminus of a core streptavidin via an optional linker.
-
145. An expression vector, comprising a transcriptional regulatory element operably linked to a nucleotide sequence encoding a C-intein fused to the amino terminus of core streptavidin via an optional linker.
-
146. A plurality of nucleic acids encoding a plurality of C-intein antigen recognition portions.
-
147. A plurality of expression vectors, each comprising a transcriptional regulatory element operably linked to a nucleotide sequence encoding a C-intein antigen recognition portion.
-
148. A kit comprising in a container a bispecific molecule having a first antigen recognition portion that binds a C3b-like receptor and a second antigen recognition portion that binds a pathogenic antigenic molecule, wherein said first antigen recognition portion comprises a monoclonal antibody, and wherein said second antigen recognition portion is conjugated to a carboxy terminus of a heavy or light chain of said first antigen recognition portion.
-
149. A kit comprising in a container a bispecific molecule comprising:
-
(a) a first antigen recognition portion that binds a C3b-like receptor;
(b) a linker; and
(c) a second antigen recognition portion that binds a pathogenic antigenic molecule;
wherein said second antigen recognition portion is conjugated to a carboxy terminus of said first antigen recognition portion via said linker.
-
-
150. A kit comprising in a container a molecule comprising:
-
(a) an antigen recognition portion that binds a C3b-like receptor; and
(b) an N-intein moiety comprising an N-intein of a split intein;
wherein said antigen recognition portion is conjugated to the amino terminal end of said N-intein moiety.
-
-
151. A kit comprising in a container a molecule comprising:
-
(a) an antigen recognition portion; and
(b) a C-intein moiety comprising a C-intein of a split intein;
wherein said antigen recognition portion is conjugated to the carboxy terminal end of said C-intein moiety, and wherein the amino acid residue immediately at the C-terminal side of the splice junction of said C-intein is an amino acid residue selected from the group consisting of cysteine, serine, and threonine.
-
-
152. A kit comprising in two containers a first molecule comprising an antigen recognition portion that binds a C3b-like receptor and an N-intein moiety comprising an N-intein of a split intein, wherein said antigen recognition portion is conjugated to the amino terminal end of said N-intein moiety;
- and a second molecule comprising an antigen recognition portion and a C-intein moiety comprising a C-intein of a split intein, wherein said antigen recognition portion is conjugated to the carboxy terminal end of said C-intein peptide, and wherein the amino acid residue immediately at the C-terminal side of the splice junction of said C-intein is an amino acid residue selected from the group consisting of cysteine, serine, and threonine.
- 153. A kit comprising in one or more containers a first vector and a second vector, said first vector comprising a first DNA sequence encoding a first antigen recognition portion that binds a C3b-like receptor fused to the amino terminus of an N-intein peptide comprising an N-intein of a split intein, said second vector comprising a second DNA sequence encoding a second antigen recognition portion fused to the carboxy terminus of a C-intein peptide comprising a C-intein of said split intein, wherein the amino acid residue immediately at the C-terminal side of the splice junction of said C-intein peptide is an amino acid residue selected from the group consisting of cysteine, serine, and threonine.
-
154. A kit comprising in one or more containers a first vector and a second vector, said first vector comprising a first DNA sequence encoding a first antigen recognition portion that binds a C3b-like receptor fused to the amino terminus of an N-intein peptide comprising an N-intein of a split intein, said second vector comprising a second DNA sequence encoding a core streptavidin fused to the carboxy terminus of a C-intein peptide comprising a C-intein of said split intein wherein the amino acid residue immediately at the C-terminal side of the splice junction of said C-intein peptide is an amino acid residue selected from the group consisting of cysteine, serine, and threonine, and in a separate container a biotinylated second antigen recognition portion.
-
155. A kit comprising a phage display library, wherein each phage displays a different C-intein polypeptide fusion protein on its surface.
-
157. A cell transformed with a vector comprising a DNA sequence encoding a first antigen recognition portion that binds a C3b-like receptor fused to the amino terminus of the N-intein of a split intein.
-
158. A cell transformed with a vector comprising a DNA sequence encoding a second antigen recognition portion fused to the carboxy terminus of a C-intein of a split intein wherein the amino acid residue immediately at the C-terminal side of the splice junction of said C-intein is an amino acid residue selected from the group consisting of cysteine, serine, and threonine.
-
159. A cell transformed with a vector comprising a DNA sequence encoding a core streptavidin fused to the carboxy terminus of a C-intein of a split intein wherein the amino acid residue immediately at the C-terminal side of the splice junction of said C-intein is an amino acid residue selected from the group consisting of cysteine, serine, and threonine.
-
160. A cell transformed with a first vector and a second vector, said first vector comprising a first DNA sequence encoding a first antigen recognition portion that binds a C3b-like receptor fused to the amino terminus of an N-intein of a split intein, said second vector comprising a second DNA sequence encoding a second antigen recognition portion fused to the carboxy terminus of a C-intein of said split intein wherein the amino acid residue immediately at the C-terminal side of the splice junction of said C-intein is an amino acid residue selected from the group consisting of cysteine, serine, and threonine.
-
161. A cell containing a first antigen recognition portion that binds a C3b-like receptor fused to the amino terminus of the N-intein of a split intein.
-
162. A cell containing a second antigen recognition portion fused to the carboxy terminus of a C-intein of a split intein, wherein the amino acid residue immediately at the C-terminal side of the splice junction of said C-intein is an amino acid residue selected from the group consisting of cysteine, serine, and threonine.
-
163. A cell containing a first antigen recognition portion that binds a C3b-like receptor fused to the amino terminus of an N-intein of a split intein and a second antigen recognition portion fused to the carboxy terminus of a C-intein of said split intein, wherein the amino acid residue immediately at the C-terminal side of the splice junction of said C-intein is an amino acid residue selected from the group consisting of cysteine, serine, and threonine.
-
164. A method of treating a mammal having a disease or disorder or undesirable condition associated with the presence of a pathogen or pathogenic antigenic molecule, comprising administering to said mammal a therapeutically effective dose of a bispecific molecule comprising:
-
(a) a first antigen recognition portion that binds a C3b-like receptor, said first antigen recognition portion comprising a monoclonal antibody; and
(b) a second antigen recognition portion that binds an epitope of said pathogen or pathogenic antigenic molecule, said second antigen recognition portion being conjugated to a carboxy terminus of a heavy or light chain of said first antigen recognition portion. - View Dependent Claims (166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181)
-
-
165. A method of preventing a disease or disorder or undesirable condition associated with the presence of a pathogen or pathogenic antigenic molecule in a mammal, comprising administering to said mammal a therapeutically effective dose of a bispecific molecule comprising:
-
(a) a first antigen recognition portion that binds a C3b-like receptor, said first antigen recognition portion comprising a monoclonal antibody; and
(b) a second antigen recognition portion that binds an epitope of said pathogen or pathogenic antigenic molecule, said second antigen recognition portion being conjugated to a carboxy terminus of a heavy or light chain of said first antigen recognition portion.
-
-
182. A method of treating a mammal having an undesirable condition associated with the presence of a pathogen or pathogenic antigenic molecule comprising the steps of:
-
(a) contacting a bispecific molecule with hematopoietic cells expressing a C3b-like receptor, to form a hematopoietic cell/bispecific molecule complex, wherein the bispecific molecule comprises (i) a first antigen recognition portion that binds said C3b-like receptor, said first antigen recognition portion comprising a monoclonal antibody; and
(ii) a second antigen recognition portion that binds an epitope of said pathogen or pathogenic antigenic molecule, said second antigen recognition portion being conjugated to a carboxy terminus of a heavy or light chain of said first antigen recognition portion; and
(b) administering said hematopoietic cell/bispecific molecule complex to said mammal in a therapeutically effective amount.
-
-
183. A method of treating a mammal having an undesirable condition associated with the presence of a pathogen or pathogenic antigenic molecule, comprising the step of administering a therapeutically effective amount of a hematopoietic cell/bispecific molecule complex to said mammal, said complex consisting essentially of a hematopoietic cell expressing a C3b-like receptor bound to one or more bispecific molecules, wherein said bispecific molecule comprises (a) a first antigen recognition portion that binds said C3b-like receptor, said first antigen recognition portion comprising a monoclonal antibody;
- and (b) a second antigen recognition portion that binds an epitope of said pathogen or pathogenic antigenic molecule, said second antigen recognition portion being conjugated to a carboxy terminus of a heavy or light chain of said first antigen recognition portion.
Specification